{"analyses":[{"ciLowerLimit":"0.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.4","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3996","paramType":"Odds Ratio (OR)","paramValue":"1.5","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.5","upperLimit":"93.9","value":"89.1"},{"groupId":"OG001","lowerLimit":"74.7","upperLimit":"91.4","value":"84.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"DCR by BICR (with Pembrolizumab) is defined as the number of participants who achieve a BOR of complete response (CR), partial response (PR), or stable disease (SD) lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg) IV or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With Pembrolizumab (TRT B)"}],"paramType":"NUMBER","populationDescription":"ITT Pembrolizumab: Participants included in the ITT population who were stratified with the intent to receive pembrolizumab in the event of the control-arm assignment.","reportingStatus":"POSTED","timeFrame":"Baseline to Progressive Disease or Death from Any Cause Up to 31 Months","title":"Percentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}